Scott M Turner
Overview
Explore the profile of Scott M Turner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Gisli Jenkins R, Scholand M, et al.
Ther Adv Respir Dis
. 2024 Nov;
18:17534666241287307.
PMID: 39512136
This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the in 2024. This study looked at a medicine called (beck-so-teh-grast) as a possible...
2.
Mooney J, Jacobs S, Lefebvre E, Cosgrove G, Clark A, Turner S, et al.
Ann Am Thorac Soc
. 2024 Nov;
22(3):350-358.
PMID: 39499805
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by dyspnea and loss of lung function. Transforming growth factor-β (TGF-β) activation mediated by α integrins is central to...
3.
Schaub J, Chen J, Turner S
Curr Opin Gastroenterol
. 2024 Jan;
40(2):85-91.
PMID: 38190346
Purpose Of Review: Current treatment options for cholangiopathies are severely limited and there is thus a critical need to identify and develop therapies. This review discusses the role of integrins...
4.
Decaris M, Schaub J, Chen C, Cha J, Lee G, Rexhepaj M, et al.
Respir Res
. 2021 Oct;
22(1):265.
PMID: 34666752
Rationale: α integrins, key regulators of transforming growth factor-β activation and fibrogenesis in in vivo models of pulmonary fibrosis, are expressed on abnormal epithelial cells (αβ) and fibroblasts (αβ) in...
5.
Alsamman S, Christenson S, Yu A, Ayad N, Mooring M, Segal J, et al.
Sci Transl Med
. 2020 Aug;
12(557).
PMID: 32817366
Hepatic stellate cells (HSCs) drive hepatic fibrosis. Therapies that inactivate HSCs have clinical potential as antifibrotic agents. We previously identified acid ceramidase (aCDase) as an antifibrotic target. We showed that...
6.
Esler W, Tesz G, Hellerstein M, Beysen C, Sivamani R, Turner S, et al.
Sci Transl Med
. 2019 May;
11(492).
PMID: 31092695
Sebum plays important physiological roles in human skin. Excess sebum production contributes to the pathogenesis of acne vulgaris, and suppression of sebum production reduces acne incidence and severity. We demonstrate...
7.
Sedgeman L, Beysen C, Allen R, Ramirez Solano M, Turner S, Vickers K
Am J Physiol Gastrointest Liver Physiol
. 2018 Aug;
315(5):G810-G823.
PMID: 30160993
Colesevelam is a bile acid sequestrant approved to treat both hyperlipidemia and type 2 diabetes, but the mechanism for its glucose-lowering effects is not fully understood. The aim of this...
8.
Shankaran M, Czerwieniec G, Fessler C, Wong P, Killion S, Turner S, et al.
J Cachexia Sarcopenia Muscle
. 2018 Apr;
9(3):540-546.
PMID: 29663711
Background: Muscle mass can be measured directly in vivo by isotope dilution, using Creatine-(methyl-d ) monohydrate (D -Cr) by mouth followed by measurement of the steady-state enrichment of D -creatinine...
9.
Beysen C, Ruddy M, Stoch A, Mixson L, Rosko K, Riiff T, et al.
Am J Physiol Endocrinol Metab
. 2018 Mar;
315(1):E126-E132.
PMID: 29558206
Fructose feeding increases hepatic de novo lipogenesis (DNL) and is associated with nonalcoholic fatty liver disease. Little is known, however, about individual variation in susceptibility to fructose stimulation of DNL....
10.
van Koppen A, Verschuren L, van den Hoek A, Verheij J, Morrison M, Li K, et al.
Cell Mol Gastroenterol Hepatol
. 2017 Dec;
5(1):83-98.e10.
PMID: 29276754
Background & Aims: The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The aim...